- Home
- YMAB vs RHLD Comparison
YMAB vs RHLD Comparison
Compare YMAB & RHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- RHLD
- Stock Information
- Founded
- YMAB 2015
- RHLD 2024
- Country
- YMAB United States
- RHLD United States
- Employees
- YMAB N/A
- RHLD N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- RHLD
- Sector
- YMAB Health Care
- RHLD
- Exchange
- YMAB Nasdaq
- RHLD NYSE
- Market Cap
- YMAB 192.4M
- RHLD 217.1M
- IPO Year
- YMAB 2018
- RHLD N/A
- Fundamental
- Price
- YMAB $4.36
- RHLD $37.22
- Analyst Decision
- YMAB Buy
- RHLD
- Analyst Count
- YMAB 11
- RHLD 0
- Target Price
- YMAB $17.55
- RHLD N/A
- AVG Volume (30 Days)
- YMAB 202.0K
- RHLD 100.9K
- Earning Date
- YMAB 08-11-2025
- RHLD 08-15-2025
- Dividend Yield
- YMAB N/A
- RHLD N/A
- EPS Growth
- YMAB N/A
- RHLD N/A
- EPS
- YMAB N/A
- RHLD 12.54
- Revenue
- YMAB $88,658,000.00
- RHLD $420,450,000.00
- Revenue This Year
- YMAB N/A
- RHLD N/A
- Revenue Next Year
- YMAB $15.15
- RHLD N/A
- P/E Ratio
- YMAB N/A
- RHLD $3.18
- Revenue Growth
- YMAB 4.92
- RHLD 11.09
- 52 Week Low
- YMAB $3.55
- RHLD $24.22
- 52 Week High
- YMAB $16.11
- RHLD $54.05
- Technical
- Relative Strength Index (RSI)
- YMAB 45.29
- RHLD N/A
- Support Level
- YMAB $4.10
- RHLD N/A
- Resistance Level
- YMAB $4.62
- RHLD N/A
- Average True Range (ATR)
- YMAB 0.29
- RHLD 0.00
- MACD
- YMAB -0.04
- RHLD 0.00
- Stochastic Oscillator
- YMAB 20.73
- RHLD 0.00
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About RHLD RESOLUTE HOLDINGS MANAGEMENT INC
Resolute Holdings Management Inc is provide operating management services. The company has two operating segments and two reportable segments: Payment Card and Arculus. Payment Card generates its revenue through the production and sale of metal payment cards while Arculus generates its revenue through the production and sale of metal payment or nonpayment cards containing Arculus technology for authentication and/or digital asset cold storage and related services. The company generates maximum revenue Domestically.